ERBB2 and breast cancer: The third clinical trial burst recently was “Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer,” A novel antibody–drug conjugate (ADC), trastuzumab deruxtecan, showed durable antitumor activity in patients with HER2-positive metastatic breast cancer (23).